Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 11,000 employees worldwide. The drug development industry has come along way in the last two decades. In the 1980s and early 1990s, when the focus was on cost-savings and capacity management, contract research organizations (CROs) they’re themed primarily as spillover capacity. The work was done and often done they’ll, but their relationship with their pharmaceutical clients was tactical, and CRO growth rates and profitability they’re volatile. From roughly 2000 to 2005, biotechnology and specialty pharmaceutical companies began to theme CROs more strategically, which stabilized demand and improved the performance and return on investment of CROs. In the late 1980s and early 1990s, Corning, Incorporated acquired numerous best-of-class drug development companies, some with roots dating back to the 1940s. In January 1997, Corning spun off these businesses as one publicly-traded, independent company called Covance Inc. Their mission is to help their clients bring the miracles of medicine to market sooner. Their vision is to be recognized by clients as the undisputed leader in providing drug development services and a trusted partner whose hallmarks are great people, high quality data, and a proven track record of integrating and streamlining development processes.